SpringWorks Therapeutics(SWTX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights ® – Achieved $49.3 million in OGSIVEO (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validatio ...